Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P134 cell therapy in recurrent glioblastoma (Phase I/II)
CTR20254510Phase 2Active
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd.
- Start
- Dec 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of P134 in glioblastoma (GBM), sponsored by Tasly Pharmaceutical Group Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
P134
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on CTR20254510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254510.